Author

M. Mohme

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Assay:flow cytometry· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1

Frequent Co-Authors

A. Piffko· 1 shared A. Ruenger· 1 shared B. Asey· 1 shared C. Maire· 1 shared D. D. Bigner· 1 shared D. M. Ashley· 1 shared E. Tolosa· 1 shared G. Emurlai· 1 shared

Activity by Year

2022-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Piffko

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

NSCLC patients with oligo-metastatic brain disease show an altered CD4 T-cells immune profile

M. Alsousli, C. Maire, A. Piffko, J. Matschke, L. Glau, M. Reetz, S. Schneegans, G. Emurlai, B. Asey, A. Ruenger, S. Peine, J. Kropidlowski, J. Gempt, M. Glatzel, M. Westphal, , H. Wikman

The paper identifies altered CD4 T-cell immune profiles in NSCLC patients with oligo-metastatic brain disease compared to poly-metastatic disease and healthy controls.

bioRxiv · Apr 10, 2024 · PreprintCancer Biology

Polio Virotherapy of Malignant Glioma Engages the Tumor Myeloid Infiltrate and Induces Diffuse Microglia Activation

Y. Yang, M. C. Brown, G. Zhang, K. Stevenson, M. Mohme, R. Kornahrens, D. D. Bigner, D. M. Ashley, G. Y. Lopez, M. Gromeier

This study investigates how PVSRIPO virotherapy activates microglia and myeloid cells in gliomas, leading to antitumor inflammation and improved outcomes when combined with PD1/PD-L1 blockade.

bioRxiv · Apr 19, 2022 · PreprintCancer Biology